THR. Oxurion NV

Publication Annual Report – Annual Shareholders' Meeting

Publication Annual Report – Annual Shareholders' Meeting

Publication Annual Report – Annual Shareholders' Meeting

Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The annual report for the year ending December 31, 2023 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF.

On this day as well, the Company has convened its Annual Shareholders' Meeting. The relevant documents pertaining to this Meeting have been published in the section “Shareholder Meetings”

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at .

Please contact for additional information:

Oxurion NV

Pascal Ghoson

Chief Executive Officer





 		Backstage Communication

Jurgen Vluijmans

Partner





 

Attachments



EN
15/04/2024

Underlying

THR.Oxurion NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oxurion NV

 PRESS RELEASE
Free
THR. OXURION NV

Oxurion Receives Transparency Notification from Atlas Special Opportun...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,755,774 shares of the then o...

April 25, 2024 1 EN
 PRESS RELEASE
Free
THR. OXURION NV

Publication Annual Report – Annual Shareholders' Meeting

Publication Annual Report – Annual Shareholders' Meeting Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The annual report for the year ending December 31, 2023 is available in the “Investors” section of the Company’s website, and can also be downloaded as a PDF. On this day as well, the Company has convened its Annual Shareholders' Meeting. The relevant documents pertaining to...

April 15, 2024 1 EN
 PRESS RELEASE
Free
THR. OXURION NV

Oxurion Receives Transparency Notifications from Atlas Special Opportu...

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Leuven, BELGIUM – April 11, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received two transparency notifications as follows: Oxurion received a first transparency notification on April 10, 2024, from Atlas Special Opportunities, LLC indicating that as of April 1, 2024, it held 1,6...

April 11, 2024 1 EN
 PRESS RELEASE
Free
THR. OXURION NV

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Pro...

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up Oxurion Receives EUR 450,000 in the framework of the Atlas Funding ProgramEleventh tranche fully issued and paid-up Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 450,000 in the framework of the Atlas Funding Program. On April 10, 2024, the Company issued the Eleventh Tranche consisting of 18 convertible bonds, for an aggrega...

April 10, 2024 1 EN
 PRESS RELEASE
Free
THR. OXURION NV

Postponement Annual Shareholders Meeting - Amendment financial calenda...

Postponement Annual Shareholders Meeting - Amendment financial calendar Postponement Annual Shareholders Meeting - Amendment financial calendarLeuven, BELGIUM – April 5, 2024 – 02:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today made the following announcement regarding its financial calendar.   Due to administrative reasons, the annual accounts of the Company have not been finalized yet. Hence, the Company has decided to postpone its Annual Shareholders Meeting to Thursday May 16, 2024. The on the Company website has been updated...

April 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch